Further Weakness as Sihuan Pharmaceutical Holdings Group (HKG:460) Drops 7.0% This Week, Taking Three-year Losses to 40%

Simply Wall StDec 19 19:10 ET

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 09:27 ET

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 01:21 ET

Beijing Centergate Technologies (000931.SZ): The company's Pharmaceutical has been included in the 2024 National Medical Insurance Directory.

On December 11, Gelonghui announced that Beijing Centergate Technologies (000931.SZ) stated that its wholly-owned subsidiary SIHUAN PHARM holds Beijing Huasu, ShanDong Huasu, and SIHUAN PHARM controlled Duoduo Pharmaceutical have a total of 34 products included in the "Medical Insurance Catalogue 2024." This includes products such as bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, which were originally included in the 2023 National Medical Insurance Catalogue. The selected products remain unchanged compared to the "Medical Insurance Catalogue 2023." The future sales situation of the included products may be affected by multiple factors such as changes in the market environment and will not impact the current operation of the company.

Gelonghui FinanceDec 11 05:09 ET

Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.

① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?

cls.cnDec 8 21:40 ET

Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).

On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.

Zhitong FinanceDec 8 20:29 ET